Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic cancer
Clémentine Gaucher, Muge Kaya, Jonathan Garnier, Anna Barthelemy, Philippe Rochigneux, Flora Poizat, Marion Rubis, Pauline Moussard, Julie Roques, Nicolas Alejandro Fraunhoffer, Nelson Dusetti, Brice Chanez
This paper evaluates transcriptomic FOLFIRINOX sensitivity signatures in neoadjuvant pancreatic cancer, finding they predict survival and show directional reclassification after treatment.
bioRxiv · Sep 9, 2026 · PreprintCancer Biology